Rheumatoid Arthritis Drugs Market (By Molecule: Pharmaceuticals, Biopharmaceuticals; By Sales Channel: Prescription, Over-the-Counter (OTC); By Route of Administration: Oral, Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Rheumatoid Arthritis Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Rheumatoid Arthritis Drugs Market, by Molecule, 2024-2033
8.1.1 Pharmaceuticals
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Biopharmaceuticals
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Rheumatoid Arthritis Drugs Market, by Sales Channel, 2024-2033
9.1.1. Prescription
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Over-the-Counter (OTC)
9.1.2.1. Market Revenue and Forecast (2021-2033)
10.1. Rheumatoid Arthritis Drugs Market, by Route of Administration, 2024-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.1.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.1.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.2.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.3.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Molecule (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Sales Channel (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2033)
12.1. AbbVie
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Boehringer Ingelheim GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Regeneron Pharmaceuticals, Inc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. UCB S.A.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson Services, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Amgen, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample